F. Clinical Renal Pharmacology and Therapeutics
- Journal Club. Oliver, Juan; Schlöndorff, Detlef // Kidney International;Apr2007, Vol. 71 Issue 7, p606
The article presents various articles submitted including "Hydronephrosis and renal abnormalities in DLGH1 mice," and "hypoxia-inducible factors is the critical factor regulating erythropoietin and erythropoiesis in the adult," both by Juan Oliver and another on immunoglobulin A nephropathy-like...
- Hydronephrosis. // Diseases & Disorders: A Nursing Therapeutics Manual, 2nd edition;2002, p453
Offers information on hydronephrosis, a condition characterized by the distension of the pelvis and calyces of one or both kidneys. Effect of the condition on kidneys; Causes of hydronephrosis; Clinical diagnosis and management of the condition.
- Erythropoietin: the developing story. Cortes, P. Mary // British Medical Journal (Clinical Research Edition);3/19/1988, Vol. 296 Issue 6625, p805
Focuses on the effects of erythropoietin in correcting anemia of renal disease. Risks in the transfusion treatment of anemia in renal chronic failure; Clinical trials on erythropoietin; Benefits from erythropoietin.
- Hydronephrosis, poor renal function can spell endopyelotomy failure. Watson, Fiona // Urology Times;Mar97, Vol. 25 Issue 3, p24
Discusses the effect of high-grade hydronephrosis and poor renal function in endopyelotomy failure. Success rate in patients with marked and moderate hydronephrosis; Success rate in patients with poor renal function; Importance of crossing vessels in endopyelotomy failure; Chances of failure of...
- Recombinant Human Erythropoietin Treatment in Pre-Dialysis Patients. Lim, Victoria S.; DeGowin, Richard L.; Zavala, Donald; Kirchner, Peter T.; Abels, Robert; Perry, Paul; Fangman, Jerry // Annals of Internal Medicine;1/15/89, Vol. 110 Issue 2, p108
Determines the efficacy and safety of recombinant human erythropoietin in predialysis renal patients. Serious complication of renal insufficiency and the most important factor limiting optimal rehabilitation in pre-dialysis renal patients; Effect of recombinant human erythropoietin on...
- The mortality risk associated with higher hemoglobin: is the therapy to blame? Rosner, Mitchell H.; Bolton, W. Kline // Kidney International;Sep2008, Vol. 74 Issue 6, p695
Recent trials have demonstrated a trend for increased mortality when patients with end-stage renal disease (ESRD) or chronic kidney disease (CKD) are treated with erythropoietin-stimulating agents (ESAs) to hemoglobin levels higher than recommended (>13 g/dl). Recent studies suggest that higher...
- Is the anemia of CKD always due to erythropoietin deficiency? Garcia, Jennifer L. // Veterinary Medicine;Aug2011, Vol. 106 Issue 8, p384
The article provides an answer to a question on the cause of the anemia of chronic kidney disease (CKD) due to erythropoietin deficiency.
- Erythropoeitin dose variation in different facilities in different countries and its relationship to drug resistance. Greenwood, Roger N.; Ronco, Claudio; Gastaldon, Fiorella; Brendolan, Alessandra; Homel, Peter; Usvyat, Len; Bruno, Lenore; Carter, Mary; Levin, Nathan W. // Kidney International Supplement;Nov2003, Issue 87, p78
Erythropoeitin dose variation in different facilities in different countries and its relationship to drug resistance. The correction of anemia using erythropoeitin (EPO) is accorded high priority in the management of patients undergoing hemodialysis (HD). Target hemoglobin (Hb) levels have been...
- Renal Disease and Failure. // Kidney;Jan/Feb2002, Vol. 11 Issue 1, p16
Presents abstracts of studies related to renal disease and failure. Renal function after shock wave lithotripsy, percutaneous nephrolithotomy and combination therapy; Impact of hydronephrosis with diffuse or segmental cortical thinning on renal function; Orthoptic bladder substitution after...